Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Hsp70 exerts oncogenic activity in the Apc mutant Min mouse model.

Tao Y, Messer JS, Goss KH, Hart J, Bissonnette M, Chang EB.

Carcinogenesis. 2016 Jul;37(7):731-9. doi: 10.1093/carcin/bgw056. Epub 2016 May 4.

PMID:
27207671
2.

β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.

Xu J, Chen Y, Huo D, Khramtsov A, Khramtsova G, Zhang C, Goss KH, Olopade OI.

Mol Carcinog. 2016 May;55(5):431-9. doi: 10.1002/mc.22292. Epub 2015 Feb 8.

PMID:
25663530
3.

β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells.

Xu J, Prosperi JR, Choudhury N, Olopade OI, Goss KH.

PLoS One. 2015 Feb 6;10(2):e0117097. doi: 10.1371/journal.pone.0117097. eCollection 2015.

4.

The APC tumor suppressor is required for epithelial cell polarization and three-dimensional morphogenesis.

Lesko AC, Goss KH, Yang FF, Schwertner A, Hulur I, Onel K, Prosperi JR.

Biochim Biophys Acta. 2015 Mar;1853(3):711-23. doi: 10.1016/j.bbamcr.2014.12.036. Epub 2015 Jan 8.

5.

Janet Davidson Rowley (1925-2013).

Goss KH, Le Beau MM.

Cancer Cell. 2014 Jan 13;25(1):1-2. No abstract available.

PMID:
24654260
6.

Targeting loss of tumor suppressors for cancer therapeutics.

Prosperi JR, Goss KH.

Curr Drug Targets. 2014 Jan;15(1):1. No abstract available.

PMID:
24428573
7.

Exploiting APC function as a novel cancer therapy.

Lesko AC, Goss KH, Prosperi JR.

Curr Drug Targets. 2014 Jan;15(1):90-102.

PMID:
24200292
8.

Regulation of Tcf7l1 DNA binding and protein stability as principal mechanisms of Wnt/β-catenin signaling.

Shy BR, Wu CI, Khramtsova GF, Zhang JY, Olopade OI, Goss KH, Merrill BJ.

Cell Rep. 2013 Jul 11;4(1):1-9. doi: 10.1016/j.celrep.2013.06.001. Epub 2013 Jun 27.

9.

APC/β-catenin-rich complexes at membrane protrusions regulate mammary tumor cell migration and mesenchymal morphology.

Odenwald MA, Prosperi JR, Goss KH.

BMC Cancer. 2013 Jan 9;13:12. doi: 10.1186/1471-2407-13-12.

10.

Apc mutation enhances PyMT-induced mammary tumorigenesis.

Prosperi JR, Khramtsov AI, Khramtsova GF, Goss KH.

PLoS One. 2011;6(12):e29339. doi: 10.1371/journal.pone.0029339. Epub 2011 Dec 22.

11.

A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer.

Prosperi JR, Goss KH.

Curr Drug Targets. 2010 Sep;11(9):1074-88. Review.

PMID:
20545611
12.

Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.

Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH.

Am J Pathol. 2010 Jun;176(6):2911-20. doi: 10.2353/ajpath.2010.091125. Epub 2010 Apr 15.

13.

The Ron receptor tyrosine kinase is not required for adenoma formation in Apc(Min/+) mice.

Meyer SE, Waltz SE, Goss KH.

Mol Carcinog. 2009 Nov;48(11):995-1004. doi: 10.1002/mc.20551.

14.

The APC tumor suppressor is required for epithelial integrity in the mouse mammary gland.

Prosperi JR, Becher KR, Willson TA, Collins MH, Witte DP, Goss KH.

J Cell Physiol. 2009 Aug;220(2):319-31. doi: 10.1002/jcp.21766.

PMID:
19326388
15.

Regulated synthesis and functions of laminin 5 in polarized madin-darby canine kidney epithelial cells.

Mak GZ, Kavanaugh GM, Buschmann MM, Stickley SM, Koch M, Goss KH, Waechter H, Zuk A, Matlin KS.

Mol Biol Cell. 2006 Aug;17(8):3664-77. Epub 2006 Jun 14.

16.

Transcriptional profiles of intestinal tumors in Apc(Min) mice are unique from those of embryonic intestine and identify novel gene targets dysregulated in human colorectal tumors.

Reichling T, Goss KH, Carson DJ, Holdcraft RW, Ley-Ebert C, Witte D, Aronow BJ, Groden J.

Cancer Res. 2005 Jan 1;65(1):166-76.

17.

Strain-specific of alachlor on murine olfactory mucosal responses.

Genter MB, Goss KH, Groden J.

Toxicol Pathol. 2004 Nov-Dec;32(6):719-25.

18.

Alternative splicing of the APC gene in the neural retina and retinal pigment epithelium.

Liou GI, Samuel S, Matragoon S, Goss KH, Santoro I, Groden J, Hunt RC, Wang F, Miller SS, Caldwell RB, Rustgi AK, Singh H, Marcus DM.

Mol Vis. 2004 Jun 14;10:383-91.

19.

Enhanced tumor formation in mice heterozygous for Blm mutation.

Goss KH, Risinger MA, Kordich JJ, Sanz MM, Straughen JE, Slovek LE, Capobianco AJ, German J, Boivin GP, Groden J.

Science. 2002 Sep 20;297(5589):2051-3.

20.

The APC tumor suppressor controls entry into S-phase through its ability to regulate the cyclin D/RB pathway.

Heinen CD, Goss KH, Cornelius JR, Babcock GF, Knudsen ES, Kowalik T, Groden J.

Gastroenterology. 2002 Sep;123(3):751-63.

PMID:
12198702
Items per page

Supplemental Content

Write to the Help Desk